Exchange Surveillance
No active ASM or GSM measures on this stock.
Price band — none
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
Lupin Limited is a transnational pharmaceutical Company. The Company is engaged in producing a range of generic and branded formulations and bulk drugs. It manufactures Active Pharmaceutical Ingredients (APIs) and several drug formulations. Its product basket consists of formulations from Cephalosporins, CVS, CNS, Anti-Asthma, Anti-TB, Diabetology, Dermatology, GI, and other therapy segments. Its APIs products include Cephalexin, Cefaclor, Cefadroxil, Cefprozil, Rifaximin, Ethambutol, Pyrazinamide, Rifampicin, Rifabutin, Lisinopril, Simvastatin, Prasugrel, Levetiracetam, Lacosamide, Eslicarbazepine Acetate, Rasagiline Mesylate, Pregabalin, Flupirtine Maleate and Febuxostat. As on March 31, 2012, the Company had 19 subsidiaries.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- Mumbai, Maharashtra
- Chairman
- Manju D Gupta
- CEO & MD
- Nilesh D Gupta
- Registrar
- Link Intime India Pvt. Ltd.
- Exchange
- NSE
- ISIN
- INE326A01037
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Lupin Ltd today?
Lupin Ltd (LUPIN) is trading at ₹1,928.9. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is LUPIN’s P/E ratio versus the sector?
LUPIN trades at a P/E of 14.7. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is LUPIN’s dividend yield?
LUPIN has a dividend yield of 0.84%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is LUPIN’s 52-week high and low?
LUPIN has traded between ₹1,892.9 and ₹2,529.5 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Lupin Ltd?
Lupin Ltd has a market capitalisation of ₹97,631 crore.
▶What is LUPIN’s return on equity?
LUPIN reports a return on equity of 21.2%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.
▶Who are LUPIN’s competitors?
The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is LUPIN’s promoter holding?
Promoters hold 46.85% of LUPIN. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include LUPIN?
Index membership is listed in the Context block on this page, along with the weight LUPIN carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Lupin Ltd a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from LUPIN’s own numbers. The judgement is yours.
LUPIN at a glance
Lupin Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector. Lupin Ltd (LUPIN) last traded at ₹1,928.9, giving it a market capitalisation of ₹97,631 crore. The 52-week range is ₹1,892.9 to ₹2,529.5, and the price is 6% of the way up that range. It trades at a price-to-earnings ratio of 14.7. Promoters hold 46.85% of the company in the latest shareholding filing.
| Market cap | ₹97,631 crore |
|---|---|
| P/E | 14.7 |
| ROE | 21.2% |
| ROCE | 26.2% |